BDKRB2 and glioblastoma: In the present study, we were able to demonstrate (1) the ability of kinin peptide B1R and B2R agonist analogs (NG29 and NG291) to improve BBB penetration of the chemotherapeutic agent DOX in rats with moderately developed F98 glioblastoma (GBM); and (2) the efficacy of B2R agonist NG291 to induce BBB opening and extravasation of HMW dextran tracers into the brain of normal mice, using intraarterial (i.a) and i.v. delivery routes, respectively (Figure 1 and Figure 2).